Local Suffolk AI experts Orbital Global have secured a world-leading €23 million Horizon AI heart failure project. They join AstraZeneca, Bayer, Novo Nordisk, Eli Lily and a range of leading European academic institutions on this project funded by Innovative Health Initiative (IHI) – run jointly by the European Commission and the European life science industry.
Orbital Global chief executive Peter Brady said: “Cardiovascular diseases affect 620 million people across the world and account for around one in three deaths globally. Despite individual differences in risk factors and symptoms, there is currently a standard treatment plan for all patients. Our vision is to deploy VirtTuri within this project, to better understand patients’ individual needs and configure tailored treatments in real time for them, ultimately saving lives.”